gsk_sign_good

GSK’s asthma drug meets primary goal in safety study for children

pharmafile | March 17, 2016 | News story | Research and Development Advair Diskus, GSK, asthma, drug trial 

GlaxoSmithKline (LSE: GSK) said on Thursday its asthma drug met the primary end point in a second study for children.

The company said its Advair Diskus medication showed non-inferiority compared to corresponding doses of fluticasone propionate, on the risk of serious asthma-related events.

The trial was conducted for children aged 4-11 years with asthma.

Advertisement

The second study was undertaken by GSK as a post-marketing requirement of the US Food and Drug Administration (FDA), the company said in a statement.

The first study, AUSTRI, which reported results in October, compared Advair Diskus, a combination of the LABA, salmeterol, and inhaled corticosteroid (ICS), fluticasone propionate (FP), to FP monotherapy, to assess the safety profiles of each medicine when used to treat adolescent and adult patients with asthma.

Anjali Shukla

Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

1nhaler receives £1.5m in funding to develop new cardboard inhaler

1nhaler, a Scotland-based developer of drug delivery devices, has received £1.5m in seed funding for …

Multiple myeloma treatment approved in Japan

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …

The Gateway to Local Adoption Series

Latest content